18
total announcements
531015.BO · 15 min delayed
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has submitted the BSE a copy of the Scrutinizer report along with voting results of the court-convened General Meeting held on October 24, 2026.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd held a court-convened general meeting on October 24, 2026, to consider and approve the proposed Scheme of Amalgamation between Hatri Pharma Private Limited and Venmax Drugs and Pharmaceuticals Limited.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has submitted a certificate under Regulation 74(5) of the SEBI(Depositories and Participants) Regulations, 2018, confirming compliance for the quarter ended September 30, 2026.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has announced the voting results and scrutinizer's report of its 37th Annual General Meeting (AGM) held on September 26, 2026, through video conferencing. All resolutions were passed with the requisite majority.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd held its 37th Annual General Meeting (AGM) on September 26, 2026, through video conferencing. The meeting was attended by 45 members, and the company's Managing Director, Mr. Venkata Rao Sadhanala, briefed shareholders on the business operations and financial performance for the FY 2025-2026. The company also announced its intention to merge with Hatri Pharma Private Limited, subject to necessary approvals.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has announced the closure of its trading window for 48 hours after declaring unaudited financial results for the quarter ended September 30, 2026. The trading window will be closed for all insiders, including designated persons and their immediate relatives, from October 1, 2026.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has published a newspaper advertisement for the meetings of the equity shareholders to be convened as per directions of the Hon'ble National Company Law Tribunal (NCLT), Hyderabad Bench-II. The meetings are scheduled to be held on October 24, 2026, at 12:30 P.M. The company has made available the complete details/documents related to the proposed merger on its website at https://www.venmaxdrugs.com/amalgamation.html.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has informed the exchange about the meeting of equity shareholders of the Company pursuant to the order passed by Hon. NCLT, Hyderabad bench II in respect of Scheme of Amalgamation of Hatri Pharma Private Limited with Venmax Drugs and Pharmaceuticals Limited.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd submitted its Annual Report for the Financial Year 2025-26, including the Notice of 37th Annual General Meeting, to be held on September 26, 2026. The report includes the Standalone Audited Financial Statements, the Report of the Directors, and the Independent Auditor's Report.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has announced the outcome of its Board Meeting, which included the approval of the Notice and Directors Report for the Financial Year 2025-2026, Secretarial Audit Report, and the date, time, and venue of the 37th Annual General Meeting. The Board also approved the appointment of Mr. Venkata Rao Sadhanala as Managing Director and the regularization of Mrs. Padmaja Kalyani Sadhanala and Mr. Revoor Ramachandra as Non-Executive Directors.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/08/2026 to consider and approve matters related to the 37th Annual General Meeting, regularization of appointment of Additional Directors, and change in designation of the Whole-time Director.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has published unaudited financial results for the quarter ended June 30, 2026, as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has filed a statement confirming that there is no deviation or variation in the use of proceeds raised through a preferential issue for the quarter ended June 30, 2026.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has announced unaudited financial results for the quarter ended June 30, 2026, along with a limited review report from its statutory auditors. The company has also approved the forfeiture of 7,80,001 partly paid-up convertible share warrants due to non-payment of the balance subscription amount within the prescribed period.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, along with a limited review report from its statutory auditors. The company has also approved the forfeiture of 7,80,001 partly paid-up convertible share warrants due to non-payment of the balance subscription amount within the prescribed period.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has scheduled a board meeting on August 7, 2026, to consider and approve unaudited financial results for the quarter ended June 30, 2026, and to consider the forfeiture of partly paid-up share warrants.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has allotted 7,53,334 equity shares to a warrant holder, Dinesh Muddu Kotian, at an issue price of Rs. 20 per share, increasing the company's paid-up capital to Rs. 14,48,39,290.
Venmax Drugs and Pharmaceuticals Ltd
Venmax Drugs and Pharmaceuticals Ltd has allotted 21,47,665 equity shares to 8 warrant holders on a preferential basis, increasing the company's paid-up capital to Rs. 13,73,05,950.